



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07C 405/00 // A61K 31/557	A1	(11) International Publication Number: WO 99/50242 (43) International Publication Date: 7 October 1999 (07.10.99)
(21) International Application Number: PCT/IB99/00480 (22) International Filing Date: 22 March 1999 (22.03.99) (30) Priority Data: 60/080,216 31 March 1998 (31.03.98) US (71) Applicant (for all designated States except US): THE PROCTER & GAMBLE COMPANY [US/US]; One Procter & Gamble Plaza, Cincinnati, OH 45202 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): deLONG, Mitchell, Anthony [US/US]; 8084 Tyler's Circle, West Chester, OH 45069 (US). AMBURGEY, Jack, Snyder, Jr. [US/US]; 265 Stockton Drive, Loveland, OH 45140 (US). WOS, John, August [US/US]; 8505 Harperpoint Drive, Cincinnati, OH 45249 (US). DE, Biswanath [US/US]; 11269 Cornell Woods Drive, Cincinnati, OH 45241 (US). SOPER, David, Lindsey [US/US]; 12075 Brisben Place, Cincinnati, OH 45249 (US). (74) Agents: REED, T., David et al.; The Procter & Gamble Company, 5299 Spring Grove Avenue, Cincinnati, OH 45217-1087 (US).		(81) Designated States: AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: C ₁₁ OXYMYL AND HYDROXYLAMINO PROSTAGLANDINS USEFUL AS FP AGONISTS <div style="text-align: center;"> <p style="text-align: right;">(I)</p> </div> (57) Abstract <p>The invention provides novel prostaglandin analogs. In particular, the present invention relates to compounds having a structure according to formula (I) wherein R₁, R₂, R₃, R₄, R₅, R₆, W, X, Z, a, b, p and q are defined below. This invention also includes optical isomers, diastereomers and enantiomers of formula (I), and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof. The compounds of the present invention are useful for the treatment of a variety of diseases and conditions, such as bone disorders and glaucoma. Accordingly, the invention further provides pharmaceutical compositions comprising these compounds. The invention still further provides methods of treatment for bone disorders and glaucoma using these compounds or the compositions containing them.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		


C₁₁ OXYMYL AND HYDROXYLAMINO PROSTAGLANDINS USEFUL AS FP AGONISTS

TECHNICAL FIELD

The subject invention relates to certain novel analogs of the naturally occurring prostaglandins. Specifically, the subject invention relates to novel Prostaglandin F analogs. The subject invention further relates to methods of using said novel Prostaglandin F analogs. Preferred uses include methods of treating bone disorders and glaucoma.

BACKGROUND OF THE INVENTION

Naturally occurring prostaglandins (PGA, PGB, PGE, PGF, and PGI) are C-20 unsaturated fatty acids. PGF_{2α}, the naturally occurring Prostaglandin F in humans, is characterized by hydroxyl groups at the C₉ and C₁₁ positions on the alicyclic ring, a cis-double bond between C₅ and C₆, and a trans-double bond between C₁₃ and C₁₄. Thus PGF_{2α} has the following formula:



Analogues of naturally occurring Prostaglandin F have been disclosed in the art. For example, see U.S. Patent No. 4,024,179 issued to Bindra and Johnson on May 17, 1977; German Patent No. DT-002,460,990 issued to Beck, Lerch, Seeger, and Teufel published on July 1, 1976; U.S. Patent No. 4,128,720 issued to Hayashi, Kori, and Miyake on December 5, 1978; U.S. Patent No. 4,011,262 issued to Hess, Johnson, Bindra, and Schaaf on March 8, 1977; U.S. Patent No. 3,776,938 issued to Bergstrom and Sjovall on December 4, 1973; P.W. Collins and S. W. Djuric, "Synthesis of Therapeutically Useful Prostaglandin and Prostacyclin Analogs", Chem. Rev. Vol. 93 (1993), pp. 1533-1564; G. L. Bundy and F. H. Lincoln, "Synthesis of 17-Phenyl-18,19,20-Trinorprostaglandins: I. The PG₁ Series", Prostaglandins, Vol. 9 No. 1 (1975), pp. 1-4; W. Bartman, G. Beck, U. Lerch, H.

Teufel, and B. Scholkens, "Luteolytic Prostaglandins: Synthesis and Biological Activity", Prostaglandins, Vol. 17 No. 2 (1979), pp. 301-311; C. Liljebris, G. Selen, B. Resul, J. Sternschantz, and U. Hacksell, "Derivatives of 17- Phenyl-18,19,20-trinorprostaglandin F₂ α Isopropyl Ester: Potential Antiglaucoma Agents", Journal of Medicinal Chemistry, Vol. 38 No. 2 (1995), pp. 289-304.


Naturally occurring prostaglandins are known to possess a wide range of pharmacological properties. For example, prostaglandins have been shown to: relax smooth muscle, which results in vasodilatation and bronchodilatation, to inhibit gastric acid secretion, to inhibit platelet aggregation, to reduce intraocular pressure, and to induce labor. Although naturally occurring prostaglandins are characterized by their activity against a particular prostaglandin receptor, they generally are not specific for any one prostaglandin receptor. Therefore, naturally-occurring prostaglandins are known to cause side effects such as inflammation, as well as surface irritation when administered systemically. It is generally believed that the rapid metabolism of the naturally occurring prostaglandins following their release in the body limits the effects of the prostaglandin to a local area. This effectively prevents the prostaglandin from stimulating prostaglandin receptors throughout the body and causing the effects seen with the systemic administration of naturally occurring prostaglandins.

Prostaglandins, especially prostaglandins of the E series (PGE), are known to be potent stimulators of bone resorption. PGF_{2 α} has also been shown to be a stimulator of bone resorption but not as potent as PGE₂. Also, it has been demonstrated that PGF_{2 α} has little effect on bone formation as compared to PGE₂. It has been suggested that some of the effects of PGF_{2 α} on bone resorption, formation and cell replication may be mediated by an increase in endogenous PGE₂ production.

In view of both the wide range of pharmacological properties of naturally occurring prostaglandins and of the side effects seen with the systemic administration of these naturally occurring prostaglandins, attempts have been made to prepare analogs to the naturally occurring prostaglandins that are selective for a specific receptor or receptors. A number of such analogs have been disclosed in the art. Though a variety of prostaglandin analogs have been disclosed, there is a continuing need for potent, selective prostaglandin analogs for the treatment of a variety diseases and conditions.

SUMMARY OF THE INVENTION

The invention provides novel PGF analogs. In particular, the present invention relates to compounds having a structure according to the following formula:



wherein R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , W , X , Z , a , b , p , and q are defined below.

This invention also includes optical isomers, diastereomers and enantiomers of the formula above, and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof.

The compounds of the present invention are useful for the treatment of a variety of diseases and conditions, such as bone disorders and glaucoma. Accordingly, the invention further provides pharmaceutical compositions comprising these compounds. The invention still further provides methods of treatment for bone disorders and glaucoma using these compounds or the compositions containing them.

DETAILED DESCRIPTION OF THE INVENTION

Terms and Definitions

"Acyl" is a group suitable for acylating a nitrogen atom to form an amide or carbamate or an oxygen atom to form an ester group. Preferred acyl groups include benzoyl, acetyl, tert-butyl acetyl, para-phenyl benzoyl, and trifluoroacetyl. More preferred acyl groups include acetyl and benzoyl. The most preferred acyl group is acetyl.

"Alkyl" is a saturated or unsaturated hydrocarbon chain having 1 to 18 carbon atoms, preferably 1 to 12, more preferably 1 to 6, more preferably still 1 to 4 carbon atoms. Alkyl chains may be straight or branched. Preferred branched alkyl have one or two branches, preferably one branch. Preferred alkyl are saturated. Unsaturated alkyl have one or more double bonds and/or one or more triple bonds. Preferred unsaturated alkyl have one or two double bonds or one triple bond, more preferably one double bond. Alkyl chains may be unsubstituted or substituted with from 1 to 4 substituents. Preferred substituted alkyl are mono-, di-, or trisubstituted.

The substituents may be lower alkyl, halo, hydroxy, aryloxy (e.g., phenoxy), acyloxy (e.g., acetoxy), carboxy, monocyclic aromatic ring (e.g., phenyl), monocyclic heteroaromatic ring, monocyclic carbocyclic aliphatic ring, monocyclic heterocyclic aliphatic ring, and amino.

"Lower alkyl" is an alkyl chain comprised of 1 to 6, preferably 1 to 4 carbon atoms.

"Aromatic ring" is an aromatic hydrocarbon ring system. Aromatic rings are monocyclic or fused bicyclic ring systems. Monocyclic aromatic rings contain from about 5 to about 10 carbon atoms, preferably from 5 to 7 carbon atoms, and most preferably from 5 to 6 carbon atoms in the ring. Bicyclic aromatic rings contain from 8 to 12 carbon atoms, preferably 9 or 10 carbon atoms in the ring. Aromatic rings may be unsubstituted or substituted with from 1 to 4 substituents on the ring. The substituents may be halo, cyano, alkyl, heteroalkyl, haloalkyl, phenyl, phenoxy or any combination thereof. Preferred substituents include halo and haloalkyl. Preferred aromatic rings include naphthyl and phenyl. The most preferred aromatic ring is phenyl.

"Bone disorder" means the need for bone repair or replacement. Conditions in which the need for bone repair or replacement may arise include: osteoporosis (including post menopausal osteoporosis, male and female senile osteoporosis and corticosteroid induced osteoporosis), osteoarthritis, Paget's disease, osteomalacia, multiple myeloma and other forms of cancer, prolonged bed rest, chronic disuse of a limb, anorexia, microgravity, exogenous and endogenous gonadal insufficiency, bone fracture, non-union, defect, prosthesis implantation and the like.

"Carbocyclic aliphatic ring" is a saturated or unsaturated hydrocarbon ring. Carbocyclic aliphatic rings are not aromatic. Carbocyclic aliphatic rings are monocyclic, or are fused, spiro, or bridged bicyclic ring systems. Monocyclic carbocyclic aliphatic rings contain from about 4 to about 10 carbon atoms, preferably from 4 to 7 carbon atoms, and most preferably from 5 to 6 carbon atoms in the ring. Bicyclic carbocyclic aliphatic rings contain from 8 to 12 carbon atoms, preferably from 9 to 10 carbon atoms in the ring. Carbocyclic aliphatic rings may be unsubstituted or substituted with from 1 to 4 substituents on the ring. The substituents may be halo, cyano, alkyl, heteroalkyl, haloalkyl, phenyl, phenoxy or any combination thereof. Preferred substituents include halo and haloalkyl. Preferred carbocyclic aliphatic rings include cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. More preferred carbocyclic aliphatic rings include cyclohexyl, cycloheptyl, and cyclooctyl.

"Halo" is fluoro, chloro, bromo or iodo. Preferred halo are fluoro, chloro and bromo; more preferred are chloro and fluoro, especially fluoro.

"Haloalkyl" is a straight, branched, or cyclic hydrocarbon substituted with one or more halo substituents. Preferred haloalkyl are C₁-C₁₂; more preferred are C₁-C₆; more preferred still are C₁-C₃. Preferred halo substituents are fluoro and chloro. The most preferred haloalkyl is trifluoromethyl.

"Heteroalkyl" is a saturated or unsaturated chain containing carbon and at least one heteroatom, wherein no two heteroatoms are adjacent. Heteroalkyl chains contain from 1 to 18 member atoms (carbon and heteroatoms) in the chain, preferably 1 to 12, more preferably 1 to 6, more preferably still 1 to 4. Heteroalkyl chains may be straight or branched. Preferred branched heteroalkyl have one or two branches, preferably one branch. Preferred heteroalkyl are saturated. Unsaturated heteroalkyl have one or more double bonds and/or one or more triple bonds. Preferred unsaturated heteroalkyl have one or two double bonds or one triple bond, more preferably one double bond. Heteroalkyl chains may be unsubstituted or substituted with from 1 to 4 substituents. Preferred substituted heteroalkyl are mono-, di-, or trisubstituted. The substituents may be lower alkyl, halo, hydroxy, aryloxy (e.g., phenoxy), acyloxy (e.g., acetoxy), carboxy, monocyclic aromatic ring (e.g., phenyl), monocyclic heteroaromatic ring, monocyclic carbocyclic aliphatic ring, monocyclic heterocyclic aliphatic ring, and amino.

"Heteroaromatic ring" is an aromatic ring system containing carbon and from 1 to about 4 heteroatoms in the ring. Heteroaromatic rings are monocyclic or fused bicyclic ring systems. Monocyclic heteroaromatic rings contain from about 5 to about 10 member atoms (carbon and heteroatoms), preferably from 5 to 7, and most preferably from 5 to 6 in the ring. Bicyclic heteroaromatic rings contain from 8 to 12 member atoms, preferably 9 or 10 in the ring. Heteroaromatic rings may be unsubstituted or substituted with from 1 to 4 substituents on the ring. The substituents may be halo, cyano, alkyl, heteroalkyl, haloalkyl, phenyl, phenoxy or any combination thereof. Preferred substituents include halo, haloalkyl, and phenyl. Preferred heteroaromatic rings include thienyl, thiazolo, purinyl, pyrimidyl, pyridyl, and furanyl. More preferred heteroaromatic rings include thienyl, furanyl, and pyridyl. The most preferred heteroaromatic ring is thienyl.

"Heteroatom" is a nitrogen, sulfur, or oxygen atom. Groups containing more than one heteroatom may contain different heteroatoms.


"Heterocyclic aliphatic ring" is a saturated or unsaturated ring containing carbon and from 1 to about 4 heteroatoms in the ring, wherein no two heteroatoms are adjacent in the ring and no carbon in the ring that has a heteroatom attached to it

also has a hydroxyl, amino, or thiol group attached to it. Heterocyclic aliphatic rings are not aromatic. Heterocyclic aliphatic rings are monocyclic, or are fused or bridged bicyclic ring systems. Monocyclic heterocyclic aliphatic rings contain from about 4 to about 10 member atoms (carbon and heteroatoms), preferably from 4 to 7, and most preferably from 5 to 6 in the ring. Bicyclic heterocyclic aliphatic rings contain from 8 to 12 member atoms, preferably 9 or 10 in the ring. Heterocyclic aliphatic rings may be unsubstituted or substituted with from 1 to 4 substituents on the ring. The substituents may be halo, cyano, alkyl, heteroalkyl, haloalkyl, phenyl, phenoxy or any combination thereof. Preferred substituents include halo and haloalkyl. Preferred heterocyclic aliphatic rings include piperzyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl and piperdyl.

"Phenyl" is a monocyclic aromatic ring which may or may not be substituted with from about 1 to about 4 substituents. The substituents may be fused but not bridged and may be substituted at the *ortho*, *meta* or *para* position on the phenyl ring, or any combination thereof. The substituents may be halo, cyano, alkyl, heteroalkyl, haloalkyl, phenyl, phenoxy or any combination thereof. Preferred substituents on the phenyl ring include halo and haloalkyl. The most preferred substituent is halo. The preferred substitution pattern on the phenyl ring is *ortho* or *meta*. The most preferred substitution pattern on the phenyl ring is *meta*.

Compounds

The subject invention involves compounds having the following structure:



In the above structure, R_1 is CO_2H , C(O)NHOH , CO_2R_7 , CH_2OH , $\text{S(O)}_2\text{R}_7$, C(O)NHR_7 , $\text{C(O)NHS(O)}_2\text{R}_7$, or tetrazole; wherein R_7 is alkyl, heteroalkyl, monocyclic carbocyclic aliphatic ring, monocyclic heterocyclic aliphatic ring, monocyclic aromatic ring, or monocyclic heteroaromatic ring. Preferred R_7 is methyl, ethyl, and isopropyl. Preferred R_1 is CO_2H , C(O)NHOH , CO_2R_7 , $\text{C(O)NHS(O)}_2\text{R}_7$, and tetrazole. Most preferred R_1 is CO_2H and CO_2R_7 .

In the above structure, W is O, NH, S, S(O), S(O)₂, or (CH₂)_m; wherein m is an integer from 0 to about 3. Preferred W is O and (CH₂)_m. Most preferred W is (CH₂)₁.

In the above structure, R₂ is H and R₃ is H or lower alkyl, or R₂ and R₃ together form a covalent bond.

In the above structure, R₄ is H, alkyl, heteroalkyl, monocyclic carbocyclic aliphatic ring, monocyclic heterocyclic aliphatic ring, monocyclic aromatic ring, or monocyclic heteroaromatic ring. Preferred R₄ is H and lower alkyl. Most preferred R₄ is H.

In the above structure, each R₅ is independently selected from the group consisting of H, CH₃, and C₂H₅. Preferred R₅ is H and CH₃. Most preferred R₅ is H.

In the above structure, X is NHR₈ or OR₈, wherein each R₈ is independently selected from the group consisting of H, acyl, alkyl, heteroalkyl, monocyclic carbocyclic aliphatic ring, monocyclic heterocyclic aliphatic ring, monocyclic aromatic ring, and monocyclic heteroaromatic ring. Preferred R₈ is H. Preferred X is OR₈. Most preferred X is OH.

In the above structure, each R₆ is independently selected from the group consisting of H, CH₃, C₂H₅, OR₈, NHR₈. Preferred R₆ is H, CH₃, C₂H₅, OR₈. Most preferred R₆ is H and CH₃.

In the above structure, Y is O, NHR₈, S, S(O), or S(O)₂, provided no carbon has more than one heteroatom attached to it. Preferred Y is O, NHR₈, and S. Most preferred Y is O.

In the above structure, Z is H, methyl, monocyclic carbocyclic aliphatic ring, monocyclic heterocyclic aliphatic ring, monocyclic aromatic ring, or monocyclic heteroaromatic ring, bicyclic carbocyclic aliphatic ring, bicyclic heterocyclic aliphatic ring, bicyclic aromatic ring, or bicyclic heteroaromatic ring, provided that when Y is S, S(O), or S(O)₂ and Z is H, q is at least 1. Preferred Z is monocyclic aromatic ring and monocyclic heteroaromatic ring. More preferred Z is thienyl and phenyl.

In the above structure, a and b are independently selected from the group consisting of single bond, cis double bond, and trans double bond. Preferred a is single bond or cis double bond, and preferred b is single bond or trans double bond.

In the above structure, p is an integer from 1 to 5, q is an integer from 0 to 5, and p + q is 1 to 5.

The invention also includes optical isomers, diastereomers and enantiomers of the above structure. Preferred stereochemistry at all stereocenters of the compounds of the invention mimic that of naturally occurring PGF_{2α}.

It has been discovered that the novel PGF analogs of the subject invention are useful for treating bone disorders, especially those that require a significant increase in bone mass, bone volume, or bone strength. Surprisingly, the compounds of the subject invention have been found to provide the following advantages over known bone disorder therapies: (1) An increase trabecular number through formation of new trabeculae; (2) An increase in bone mass and bone volume while maintaining a more normal bone turnover rate; and/or (3) An increase in bone formation at the endosteal surface without increasing cortical porosity.


In order to determine and assess pharmacological activity, testing of the subject compounds in animals is carried out using various assays known to those skilled in the art. For example, the bone activity of the subject compounds can be conveniently demonstrated using an assay designed to test the ability of the subject compounds to increase bone volume, mass, or density. An example of such assays is the ovariectomized rat assay.

In the ovariectomized rat assay, six-month old rats are ovariectomized, aged 2 months, and then dosed once a day subcutaneously with a test compound. Upon completion of the study, bone mass and/or density can be measured by dual energy x-ray absorptometry (DXA) or peripheral quantitative computed tomography (pQCT), or micro computed tomography (mCT). Alternatively, static and dynamic histomorphometry can be used to measure the increase in bone volume or formation.

Pharmacological activity for glaucoma can be demonstrated using assays designed to test the ability of the subject compounds to decrease intraocular pressure. Examples of such assays are described in the following reference, incorporated herein: C. Liljebris, G. Selen, B. Resul, J. Sternschantz, and U. Hacksell, "Derivatives of 17- Phenyl-18,19,20-trinorprostaglandin F₂ α Isopropyl Ester: Potential Antiglaucoma Agents", Journal of Medicinal Chemistry, Vol. 38 No. 2 (1995), pp. 289-304.

Compounds useful in the subject invention can be made using conventional organic syntheses. Particularly preferred syntheses are the following two general reaction schemes:

Scheme 1



In **Scheme 1**, R₁, R₂, R₃, R₄, R₅, R₆, X, Y, p, q, and Z are as defined above unless otherwise defined. The Methyl 7[3-(R)-hydroxy-5-oxo-1-cyclopent-1-yl] heptanoate (**S1a**) depicted as starting material for **Scheme 1** is commercially available (such as from Sumitomo Chemical or Cayman Chemical).

In the above **Scheme 1**, Methyl 7-[3-(R)-hydroxy-5-oxo-1-cyclopent-1-yl] heptanoate (**S1a**) is reacted with a silylating agent and base in a solvent that will allow the silylation to proceed. Preferred silylating agents include tert-butyldimethylsilyl chloride and tert-butyldimethylsilyl trifluoromethanesulphonate. The most preferred silylating agent is tert-butyldimethylsilyl trifluoromethanesulphonate. Preferred bases include triethylamine, trimethylamine, and 2,6-lutidine. More preferred bases include triethylamine and 2,6-lutidine. The most preferred base is 2,6-lutidine. Preferred solvents include halocarbon solvents with dichloromethane being the most preferred solvent. The reaction is allowed to proceed at a temperature preferably between -100°C and 100°C, more preferably between -80°C and 80°C, and most preferably between -70°C and 23°C.

The resulting silylated compound is isolated by methods known to those of ordinary skill in the art. Such methods include, but are not limited to, extraction, solvent evaporation, distillation, and crystallization. Preferably, the silyl ether is purified after isolation by distillation under vacuum.

The silylated compound is then reacted with the cuprate generated via Grignard formation of the appropriate alkenyl bromide as disclosed, for example, in the following references: H.O. House et. al., "The Chemistry of Carbanions: A Convenient Precursor for the Generation of Lithium Organocuprates", J. Org. Chem. Vol. 40 (1975) pp. 1460-69 ; and P. Knochel et. al., "Zinc and Copper Carbenoids as Efficient and Selective *α*/*d*' Multicoupling Reagents", J. Amer. Chem. Soc. Vol. 111 (1989) p. 6474-76. Preferred alkenyl bromides include 4-bromo-1-butene, 4-bromo-1-butyne, 4-bromo-2-methyl-1-butene, and 4-bromo-2-ethyl-1-butene. The most preferred alkenyl bromide is 4-bromo-1-butene. Preferred solvents include ethereal solvents, of which diethyl ether and tetrahydrofuran are preferred. The most preferred solvent is tetrahydrofuran. The Grignard reagent is allowed to form at a temperature between 100°C and 23°C, more preferably between 85°C and 30°C, and most preferably between 75°C and 65°C. The reaction time is preferably between 1 hour and 6 hours, with a more preferred reaction time being between 2 hours and 5 hours, and the most preferred reaction time being between 3 hours and 4 hours.

Once the Grignard reagent is formed, the cuprate is generated from the alkenyl magnesium species. The temperature range for cuprate formation is between -100°C and 0°C . The preferred temperature range is between -80°C and -20°C . The more preferred temperature range is between -75°C and -50°C . The preferred reaction time is between 30 minutes and 6 hours. The more preferred reaction time is between 45 minutes and 3 hours. The most preferred reaction time is between 1 hour and 1.5 hours.

The compound depicted as **S1b** is isolated by methods known to one of ordinary skill in the art. Such methods include, but are not limited to, extraction, solvent evaporation, distillation, and crystallization. Preferably, **S1b** is purified by flash chromatography on silica gel (Merck, 230-400 mesh) using 10% EtOAc/hexanes as the eluent.

S1b is then reacted with a hydride reducing agent and a polar, protic solvent to give the C9 alcohol. Preferred reducing agents include lithium aluminum hydride, sodium borohydride, and L-selectride. More preferred reducing agents include sodium borohydride, and L-selectride. The most preferred reducing agent is sodium borohydride. Preferred solvents include methanol, ethanol, and butanol. The most preferred solvent is methanol. The reduction is carried out at a temperature between -100°C and 23°C . The preferred temperature range is between -60°C and 0°C . The most preferred temperature range is between -45°C and -20°C .

The resulting alcohol of **S1b** is isolated by methods known to one of ordinary skill in the art. Such methods include, but are not limited to, extraction, solvent evaporation, distillation, and crystallization. Preferably, the alcohol is purified by flash chromatography on silica gel (Merck, 230-400 mesh) using 20% EtOAc/hexanes as the eluent.

The alcohol can be protected as described previously herein. The protected or unprotected alcohol is then treated with meta-chloroperoxybenzoic acid in a halocarbon solvent to provide the novel epoxide intermediate depicted as **S1c**. Preferred halocarbon solvents include dichloromethane, dichloroethane, and chloroform. More preferred halocarbon solvents are dichloromethane and dichloroethane. The most preferred halocarbon solvent is dichloromethane.

The compound depicted as **S1c** is isolated by methods known to one of ordinary skill in the art. Such methods include, but are not limited to, extraction, solvent evaporation, distillation, and crystallization. Preferably, **S1c** is purified by flash chromatography on silica gel (Merck, 230-400 mesh) using 20% EtOAc/hexanes as the eluent.

The intermediate epoxide depicted as **S1c** can be reacted with a variety of oxygen, sulfur and nitrogen containing nucleophiles as disclosed, for example, in J.G. Smith, "Synthetically Useful Reactants of Epoxides", *Synthesis* (1984) p. 629-656, to provide the C₁₁-protected 13,14-dihydro-15-substituted-16-tetranor prostaglandin F₁ α derivatives.

With sulfur nucleophiles, the reaction is carried out preferably between 150°C and 0°C, more preferably between 120°C and 20°C, and most preferably between 80°C and 50°C. Preferred bases for the reaction include triethylamine, N,N diisopropylethylamine, and trimethylamine. The most preferred base is triethylamine. Preferred solvents for the reaction are aromatic hydrocarbon solvents. Preferred solvents include xylenes, toluene, and benzene. The most preferred solvent is benzene. With nitrogen and oxygen nucleophiles, preferred solvents include ethereal solvents and polar, protic solvents. More preferred ethereal solvents include diethyl ether, dibutyl ether and tetrahydrofuran. The most preferred ethereal solvent is tetrahydrofuran. More preferred polar, protic solvents include ethyl alcohol, methyl alcohol, and tert-butyl alcohol. The most preferred polar, protic solvent is ethyl alcohol.

The ring-opening process with nitrogen and oxygen nucleophiles can be catalyzed with Lewis acids. Preferred Lewis acids include magnesium perchlorate, trimethylsilyl trifluoromethanesulphonate, and trimethylaluminum. The most preferred Lewis acid is magnesium perchlorate. The reaction is carried out at a temperature between 150°C and 23°C, preferably between 125°C and 40°C, and more preferably between 100°C and 75°C.

The selective protection of C-9 and C-15 can be accomplished by methods known to one of ordinary skill in the art. Preferred protecting groups include, but are not limited to acylating agents, alkylating agents, and carbonate forming agents. The most preferred protecting group is acetyl. Preferred solvents include halohydrocarbon and amine solvents. The most preferred is pyridine. Preferred reagents include acetyl halides and acetic anhydride. The most preferred is acetic anhydride. The temperature range for the reaction is -100°C to 100°C. The preferred range is -10°C to 40°C. More preferred range is -5°C to 30°C. The preferred reaction time is 1 hour to 48 hours. More preferred is 6 hours to 24 hours.

The compound depicted as **S1d** is isolated by methods known to one of ordinary skill in the art. Such methods include, but are not limited to, extraction, solvent evaporation, distillation, and crystallization. Preferably, **S1d** is purified by flash chromatography on silica gel (Merck, 230-400 mesh) using 10% EtOAc/hexanes as the eluent.

The resulting C-11 ether on compound **S1d** is deprotected using using a fluoride equivalent. The deprotection reagents include tetrabutyl ammonium fluoride, hydrogen fluoride in pyridine, potassium fluoride, and treatment with strong acid. Preferred is HF/pyridine. The temperature range is -100°C to 50°C. The preferred temperature range is -50°C to 30°C. The most preferred is -20°C to 10°C. The preferred solvents are THF, Acetonitrile, and Et₂O. Most preferred is acetonitrile.

The compound is isolated by methods known to one of ordinary skill in the art. Such methods include, but are not limited to, extraction, solvent evaporation, distillation, and crystallization. Preferably the compound is purified by flash chromatography on silica gel (Merck, 230-400 mesh) using 20% EtOAc/hexanes as the eluent.

Compound **S1e** is produced by the oxidation of the C-11 alcohol to give the ketone. The oxidation can be accomplished by, but are not limited to, Swern, Jones, PCC, PDC. The most preferred is PCC. The most preferred solvent is dichloromethane. The preferred reaction temperature is -30°C to 100°C. The most preferred is 0°C to 50°C. Compound **S1e** is isolated by methods known to one of ordinary skill in the art. Such methods include, but are not limited to, extraction, solvent evaporation, distillation, and crystallization. Preferably the compound is purified by filtering through Florcil and solvent evaporation.

Compound **S1f** is formed by the reaction of NH₂OR₄ in buffered solution of solvents. The preferred buffer is sodium acetate. The preferred solvent ratio is 3:1:1 (methanol:dioxane:water). The preferred temperature range is -20°C to 100°C. The compound depicted as **S1f** is isolated by methods known to one of ordinary skill in the art. Such methods include, but are not limited to, extraction, solvent evaporation, distillation, and crystallization. Preferably, **S1f** is purified by flash chromatography on silica gel (Merck, 230-400 mesh) using 10% EtOAc/hexanes as the eluent.

Deprotection of **S1f** is accomplished by methods known to one of ordinary skill in the art and yields compounds of **Formula I**. Compounds depicted by **Formula I** are exemplified in **Examples 1-15**.

Reduction of the oxime of **S1f** gives the compound **S1h** as the hydroxyl amine. The reduction is accomplished by treatment with sodium cyanoborohydride. The preferred solvent is MeOH. The preferred temperature range is -100°C to 100°C.

Deprotection of **S1h** is accomplished by methods known to one of ordinary skill in the art and yields compounds of **Formula II**. Compounds depicted by **Formula II** are exemplified in **Examples 29-34**.

Scheme 2

In **Scheme 2**, R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , W , X , Z , and P are as defined above unless otherwise defined. The Corey Aldehyde (**S2a**) depicted as starting material for **Scheme 2** is commercially available (such as from Aldrich Chemical or Cayman Chemical).

In the above **Scheme 2**, Corey Aldehyde is commercially-available with either a silyl group (P_1) or an ester group (P_1) attached to the alcohol. The preferred protecting groups include *tert*-butyldimethylsilyl, acetate, benzoate, and *para*-phenyl benzoate. The most preferred protecting group is *tert*-butyldimethylsilyl.

The Corey aldehyde (**S2a**) is first reacted with an aldehyde protecting group to make a ketal or acetal. Examples of this type of protection are found in Greene and Wuts, Protecting Groups in Organic Synthesis, 2d ed., Wiley & Sons, N.Y. 1991. In this case, especially preferred are cyclic ketals and acetals. The aldehyde (**S2a**) is reacted with the appropriate 1,2- diol and a suitable acidic catalyst. The solvent can be the diol, and an anhydrous solvent, such as ether or dichloromethane. Particularly useful is 1,2-*bis*-TMS ethylene glycol to effect this transformation in ether at room temperature.

The ketal-protected **S2a** may then undergo a routine of protection/deprotection if desired, to exchange the P_1 group for a more suitable one, using procedures known in the art. Particularly useful is the exchange of a silyl group for an acyl group, and *vice versa*. Also useful is the exchange of a silyl or acyl group for an *o*-bromo-benzyl ether group.

The compound (**S2b**) is then subjected to a DIBAL reduction to make the hemiacetal. This intermediate is not isolated but reacted as soon as possible with a Wittig salt to form an alkene (**S2c**). Particularly preferred Wittig salts are derived from omega bromo- four to five carbon straight chain carboxylic acids and 3-oxo-carboxylic acids. These are conveniently combined with triphenylphosphine in a suitable solvent to form the reactive Wittig salts. Other preferred reagents include straight chain *omega*-bromo tetrazoles and primary nitriles.

The compound (**S2c**) is not isolated, but reacted crude with diazomethane in diethyl ether or, preferably, with TMS diazomethane in methanol to give **S2d**. In addition, a suitable protecting group may be placed on the C_9 alcohol at this time. The compound **S2d** is isolated by methods known to one of ordinary skill in the art. Such methods include, but are not limited to, extraction, solvent evaporation, distillation, and crystallization. Preferably, it is purified by flash chromatography on silica gel (Merck, 230-400 mesh) using 10% EtOAc/hexanes as the eluent.

The compound (**S2d**) is then optionally reduced at C-5,6 to give the saturated alpha chain of the prostaglandin, if desired, or taken on without reduction. The cyclic ketal is removed with acid or acidic ion exchange resin in a suitable solvent to give the free aldehyde. Preferred solvents include THF/water mixtures.

The resulting aldehyde (**S2e**) is not isolated but reacted with ketone-stabilized phosphonium salts. These are generally referred to as "Wadsworth-Horner-Emmons" reagents. This reaction requires a mild base. Examples of suitable bases include sodium carbonate or triethyl amine. The product ketone (**S2f**) is purified by methods known to one of ordinary skill in the art. Such methods include, but are not limited to, extraction, solvent evaporation, distillation, and crystallization. Preferably, the ketone (**S2f**) is purified by flash chromatography on silica gel (Merck, 230-400 mesh) using 20% EtOAc/hexanes as the eluent.

As seen in **Scheme 2** above, the ketone (**S2f**) can be reacted in three ways. Reduction of the ketone with a reducing agent such as the Luche reagent, effects an alcohol at C-15, as illustrated by **S2g**.

At this point, the alcohols of **S2g** at C-9 and C-15 may be protected, if needed or desired. If so, the alcohols can be protected as described previously herein. The **S2g** compound containing protected or unprotected alcohols is then treated with a deprotecting agent to release selectively P₁ on C-11. Examples of such selective deprotection reactions are given in Greene and Wuts.

Alternatively, when P₁ is the *o*-bromobenzyl ether, reduction of the bromine with a radical reducing agent such as (n-Bu)₃SnH will cause the radical-induced oxidation of C-11 to the ketone without needing protection.

Compounds of the type **S2h** can be converted into compounds of **Formula III** and **Formula IV**. Compounds depicted by **Formula III** are exemplified in **Examples 16-28**. Compounds depicted by **Formula IV** are exemplified in **Examples 35-40**.

The ketone (**S2f**) can also be converted into compounds of the type **S2l**. This occurs by the addition of suitable nucleophile to the ketone (**S2f**). Examples of nucleophiles include methyl magnesium bromide. Using substantially the same techniques described above, the compounds of the type **S2l** can be converted into compounds of **Formula V**, and compounds of **Formula V** can be converted into compounds of **Formula VI**. Compounds depicted by **Formula V** are exemplified in **Examples 41-43**, and compounds depicted by **Formula VI** are exemplified in **Example 44**.

Compounds of the type **S2f** can also be reacted to give compounds of the type **S2m** by reacting the ketone at C-15 with an active amine. Examples of reactive

amines include methyl amine and ethyl amine. The products can be reduced or can react with nucleophiles using standard techniques, and the reduction can also extend to reduce the alkenes, if desired, using a reagent such as hydrogen gas over palladium on carbon. Alternatively, sodium cyanoborohydride will selectively reduce the imine without disrupting the alkenes. Finally, a suitable nucleophile, preferably such as a methyl cerium reagent, can add to the imine. Addition of the methylcerium nucleophile (~1.5 equiv.) is described in T. Imamoto, et al., "Carbon-Carbon Bond Forming Reactions Using Cerium Metal or Organocerium (III) Reagents", *J. Org. Chem.* Vol. 49 (1984) p. 3904-12; T. Imamoto, et al., "Reactions of Carbonyl Compounds with Grignard Reagents in the Presence of Cerium Chloride", *J. Am. Chem. Soc.* Vol. 111 (1989) p. 4392-98; and references cited therein, gives the aminomethyl derivative. In that case, R₃ in compound **S1n** would be a methyl group.

Using the reactions disclosed above for compounds of the type **S2h**, compounds of **Formula VII** can be made from **S2n**. Compounds depicted by **Formula VII** are exemplified in **Example 45**. Compounds of the **Formula VIII** can thus be made from compounds of **Formula VII**. Compounds depicted by **Formula VII** are exemplified in **Examples 46**.

Compounds of **Formula IX** can be made from sulfonation or hydroxylation of compounds of **Formula III**. Compounds depicted by **Formula IX** are exemplified in **Examples 47-48**.

These compounds are isolated by methods known to one of ordinary skill in the art. Such methods include, but are not limited to, extraction, solvent evaporation, distillation, and crystallization.

The following non-limiting examples illustrate the compounds, compositions, and uses of the present invention.

Examples


Compounds are analyzed using ¹H and ¹³C NMR, Elemental analysis, mass spectra, high resolution mass spectra and/or IR spectra as appropriate.

Typically, inert solvents are used, preferably in dried form. For example, tetrahydrofuran (THF) is distilled from sodium and benzophenone, diisopropylamine is distilled from calcium hydride and all other solvents are purchased as the appropriate grade. Chromatography is performed on silica gel (70-230 mesh; Aldrich) or (230-400 mesh; Merck) as appropriate. Thin layer chromatography analysis is performed on glass mounted silica gel plates (200-300

mesh; J.T. Baker) and visualized using *uv* light, 5% phosphomolybdic acid in EtOH, or ammonium molybdate/ceric sulfate in 10% aqueous H₂SO₄.

Example 1

Preparation of 11-oximyl-13,14-dihydro-16-phenylthio-16-tetranor PGD₁α (1j):



a. **Methyl 7-(2-oxo-4-(1,1,2,2-tetramethyl-1-silapropoxy)cyclopent-1-enyl) heptanoate (1a):** To a solution of Methyl-7-[3-(R)-hydroxy-5-oxo-1-cyclopenten-1-yl] heptanoate (1 equiv.) in CH₂Cl₂ at -78°C is added 2,6 lutidine (1.3 equiv.) dropwise over 15 minutes. The solution is kept at -78°C, and TBDMS Triflate (1.2 equiv.) in CH₂Cl₂ is added dropwise over 15 minutes. The reaction is warmed gradually to room temperature and stirred at room temperature for 15 hours. Aqueous 10% HCl is added and the layers are separated. The water layer is extracted with CH₂Cl₂ and the organic layers are combined. The organic layer is washed with brine, dried (Na₂SO₄) and concentrated. The residue is distilled under vacuum (10 mm Hg) to provide the silyl ether **1a** as a yellow liquid.

b. **Methyl 7-(5-but-3-enyl-2-hydroxy-4-(1,1,2,2-tetramethyl-1-silapropoxy) cyclopentyl) heptanoate (1c):** To a slurry of Mg⁰ powder (2 equiv.) in THF at room temperature is added one crystal of I₂ and 1-bromobutene (2 equiv.) dropwise over 10 minutes. The reaction proceeds to exotherm as the addition continues. After the addition is complete, the reaction is refluxed for 3 hours and cooled to room temperature. The Grignard is diluted with THF and added via cannula to a 3-necked flask equipped with mechanical stirring and charged with CuBr.DMS (2 equiv.) in a 1:1 solution of THF/DMS at -78°C. After the addition of the Grignard (~20 min), the reaction is stirred for 1 hour at -78°C. The color of the reaction is dark red at this point. A solution of the ketone **1a** (1 equiv.) in THF is then added dropwise over 25 minutes. The reaction is stirred at -78°C for 15 minutes, then allowed to warm slowly to room temperature over 2 hours. The reaction is quenched with aqueous NH₄Cl and the excess DMS is allowed to evaporate overnight. The reaction is partitioned between brine/CH₂Cl₂ and the layers are separated. The aqueous layer is back-extracted with CH₂Cl₂ and the organic layers are combined and dried (Na₂SO₄). The solvent is removed in vacuo and the residue is chromatographed on SiO₂ (10 % hexane/EtOAc) to give the ketone **1b** as a clear oil.

The ketone **1b** (1 equiv.) is dissolved in MeOH and cooled to -40°C. Sodium borohydride (0.9 equiv.) is added portionwise over 10 minutes. After the addition is complete, the reaction is stirred for 13 hours at -40°C and then for 12 hours at -78°C. The reaction is quenched with water, partitioned between brine and CH₂Cl₂, and the layers separated. The aqueous layer is back-extracted with CH₂Cl₂ and the organic layers are combined and dried (Na₂SO₄). The solvent is removed in vacuo and the residue chromatographed on SiO₂ (30 % EtOAc/hexanes) to give the alcohol **1c** as a colorless oil.

c. **Methyl 7-(2-hydroxy-5-(2-(2-oxiranyl)ethyl)-4-(1,1,2,2-tetramethyl-1-sila-propoxy)cyclopentyl) heptanoate (1d):** The alcohol **1c** (1 equiv.) is dissolved in CH_2Cl_2 and cooled to 0°C . Sodium bicarbonate is added, followed by m-CPBA (57%-85% purity) (3 equiv.) portionwise over 15 minutes. After the addition is complete, the reaction is stirred for 20 hours at room temperature. The reaction is poured into water, partitioned between brine and CH_2Cl_2 , and the layers are separated. The aqueous layer is back-extracted with CH_2Cl_2 and the organic layers are combined and dried (Na_2SO_4). The solvent is removed in vacuo and the residue is chromatographed on SiO_2 (20% EtOAc/hexanes) to give the epoxide diastereomers **1d** as a colorless oil.

d. **13,14-dihydro-16-phenylthio tetranor PGF $_1\alpha$ (1e):** In a 5 mL round-bottomed flask, epoxide **1d** (1 equiv.) and 100 μL of dry benzene are added. The flask is cooled to 0°C , then is treated with 60 μL of thiophenol (1.2 eq) and 78 μL of triethyl amine (1.2 eq) as disclosed in J.G. Smith, "Synthetically Useful Reactants of Epoxides", *Synthesis* (1984) p. 629-656, and references cited therein. The ice bath is removed and the reaction is stirred at room temperature under nitrogen overnight. TLC is used to monitor the reaction. Excess thiophenol is added if necessary. The reaction is quenched with brine and is extracted with methylene chloride. The organic layer is washed three times with 1N HCl, brine, dried over sodium sulfate, and concentrated to yield **1e**.

e. **Methyl 9,15-acetyl 13,14-dihydro-16-phenylthio tetranor PGF $_1\alpha$ (1g):** In a 25 mL round-bottom flask, diol **1e** (1 equiv.) and of acetic anhydride (2 mL) is stirred in pyridine (10 mL) overnight. The reaction is concentrated under reduced pressure. The residue is dissolved in dichloromethane (40 mL) and washed 2 times with 1 N HCl. The organic layer is dried with MgSO_4 and solvent removed in vacuo leaving crude (**1f**).

The crude **1f** is treated with HF/pyridine (6 equiv.) in dry acetonitrile (10 mL). The mixture is stirred at 0°C for 2 hours and concentrated under reduced pressure. The crude material is flashed on a silica gel column using 30% ethyl acetate in hexane. Appropriate fractions were pooled and concentrated giving (**1g**) as a colorless oil.

f. **Methyl 9,15-acetyl 13,14-dihydro-16-phenylthio tetranor PGD $_1\alpha$ (1h):** In a 50 mL round-bottom flask, alcohol **1g** (1 equiv.) is added to dichloromethane (20 mL) with 10 grams of powdered molecular sieves. PCC (3 equiv.) is then added.

and the solution is stirred overnight. The mixture is filtered through Floracil and concentrated to a yellow oil (1h).

g. Methyl 9,15-acetyl 11-oximyl-13,14-dihydro-16-phenylthio tetranor PGD₁α (1i): In a 25 mL round bottom flask is added ketone 1h (1 equiv.), sodium acetate (9 equiv.), and hydroxyl amine (2 equiv.); in 3:1:1 (MeOH: dioxane: water) (5 mL). The solution is stirred overnight, and ether (50 mL) is added. The organic layer is then washed with 1N HCl and brine. The organic layer is then dried with MgSO₄ and concentrated under reduced pressure. The crude material is flashed on silica gel using 30% ethyl acetate in hexane. Appropriate fractions were collected and concentrated to a yellow liquid (1i).

h. 11-oximyl-13,14-dihydro-16-phenylthio-16-tetranor PGD₁α (1j): In a 15 mL round-bottom flask is added 1i (1 equiv.), and LiOH (3 equiv.) in 3:1 (THF:water). The mixture is stirred overnight and concentrated under reduced pressure. The residue is flashed on a silica gel column in 5% MeOH:dichloromethane with 0.1% acetic acid. Appropriate fractions were combined, and concentrated to give a colorless oil (1j).




Examples 2-15

Examples 2-15 are prepared using substantially the same procedures as those described in **Example 1**, substituting the appropriate starting materials. The skilled artisan may change temperature, pressure, atmosphere, solvents or the order of reactions as appropriate. Additionally, the skilled artisan may use protecting groups to block side reactions or increase yields as appropriate. All such modifications can readily be carried out by the skilled artisan in the art of organic chemistry, and thus are within the scope of the invention.




Example 2

11-oximyl-13,14-dihydro-16-(2,4-difluorophenylthio)-16-tetranor-PGD₁ methyl ester




22


**Example 3****11-oximyl-13,14-dihydro-16-(2,4-difluorophenoxy)-16-tetranor PGD₁****Example 4****11-oximyl-13,14-dihydro-16-aza-17-(2,4-fluorophenyl)-17-trinor-PGD₁
methyl ester****Example 5****11-oximyl-13,14-dihydro-16-(4-fluorophenylthio)-16-tetranor PGD₁ ethyl ester**

23


**Example 6****11-oximyl- 13,14- dihydro-16- (4-fluorophenoxy)-16-tetranor PGD₁****Example 7****11-oximyl- 13,14- dihydro-16- (3-chlorophenoxy)-16-tetranor PGD₁****Example 8****11-oximyl-13,14-dihydro-16-methyl-16-(3-chlorophenoxy)-16-tetranor PGD₁**

24


**Example 9****11-oximyl-13,14-dihydro-16-(2-methoxyphenylthio)-16-tetranor PGD₁****Example 10****11-oximyl-13,14-dihydro-16-(3-methoxyphenylthio)-16-tetranor PGD₁
isopropyl ester****Example 11****11-oximyl-13,14-dihydro-16-(thiomethyl-(2-thienyl))-16-tetranor PGD₁
methyl ester**

**Example 12**

11-oximyl-13,14-dihydro-16-((3-trifluoromethyl)phenoxy)-16-tetranor PGD₁ methyl ester



**Example 13**


11-oximyl-13,14-dihydro-16-(2-methylphenoxy)-16-tetranor PGD₁ glyceryl ester

**Example 14**

11-oximyl-13,14-dihydro-16-(3-methylphenylthio)-16-tetranor PGD₁

26

**Example 15****11-oximyl-13,14-dihydro-16-phenylthio-16-tetranor PGD₁ methyl ester****EXAMPLE 16****Preparation of 11-oximyl-16-(2-fluorophenoxy)-16-tetranor-PGD₂ α (1n):**



a. **7-benzoyloxy-6-(2,5-dioxolanyl)-2-oxabicyclo[3.3.0]octan-3-one (16b):** In a round bottom flask equipped with a magnetic stir bar is placed 1,2-bis(trimethylsilyloxy) ethane in methylene chloride at -78°C. To this is added, within 20 minutes, a solution of 16a in CH₂Cl₂. The reaction is stirred for 1 hour at -78°C and then slowly warmed to 25°C for 1 hour. The reaction is quenched at 0°C with water, extracted with methylene chloride, is dried over MgSO₄, and is concentrated *in vacuo* to give crude 16b (FW = 318.32 g/mole).

b. **6-(2,5-dioxolanyl)-7-hydroxy-2-oxabicyclo[3.3.0]octan-3-one (16c):** To a well stirred solution of crude 16b (63.85 g, 201 mmol, 1 eq) in methanol (786 mL) at 0°C

is added a suspension of sodium methoxide (13.27 g, 246 mmol, 1.2 eq) in MeOH (98.3 mL). The reaction is stirred at 0°C for 1 hour and then is warmed to 25°C for 1 h. The reaction is neutralized with acidic ion exchange resin which has been washed thoroughly with MeOH (5 x 100 mL). The filtrate is concentrated *in vacuo* to give a syrup which is subjected to flash chromatography on silica gel eluting with 4:1 hexane : ethyl acetate and 2% MeOH in CH₂Cl₂ to give **16c** as a yellow syrup.

c. **6-(2,5 dioxolanyl)-2-oxa-7-(o-bromobenzyloxy) bicyclo [3.3.0] octan-3-one (16d)**: In a round bottom flask with a magnetic stir bar, is stirred a solution of **16c** in CH₂Cl₂. To this solution is added dropwise at -78°C a suspension of NaH. The reaction is stirred for 30 minutes at -78°C and then *ortho*-bromo benzyl bromide is added and the reaction is warmed to 25°C overnight. The reaction is quenched with water (100 mL). The organic layer is washed with water (3 x 100 mL), dried over MgSO₄, and concentrated *in vacuo* to give a yellow oil which is subjected to flash chromatography on silica gel eluting with hexanes then 1% MeOH in CH₂Cl₂. The product is then washed with 1N HCl, 0.1N HCl, water and brine to give **16d**.

d. **Methyl 7-(5-(2,5-dioxolanyl)-2-hydroxy-4-(o-bromobenzyloxy) cyclopentyl) hept-5-enoate (16f)**: In a round bottom flask with a magnetic stir bar, is stirred a solution of **16d** in dry toluene. To this solution, at -78°C, is slowly added DIBAL in hexane. The reaction mixture is stirred for 2 hours and then warmed to 0°C. Saturated is added to the reaction mixture which is then slowly warmed to 25°C. Diluted with water (100 mL), the insoluble precipitate is removed by suction filtration and the solid is washed with EtOAc (2 x 25 mL). The liquid phase is extracted with EtOAc (3 x 50 mL) and the combined organic phase is dried over MgSO₄ and is concentrated *in vacuo* to give a yellow syrup. The product, **16e**, must either be used immediately or stored at -70°C overnight. To a suspension of (4-carboxybutyl)triphenylphosphonium in THF at 0°C under Nitrogen is added dropwise a solution of KHMDS in toluene. The resulting deep orange colored reaction mixture is stirred for 1 hour at 25°C. To the reaction mixture above at -78°C is added a solution of **16e** in THF. The reaction mixture is allowed to warm to 25°C overnight. The reaction is quenched with water at 0°C and the pH is adjusted to 3.5 - 4.0 with 1N HCl. The water phase is extracted with EtOAc and the combined organic phase is dried over MgSO₄ and is concentrated *in vacuo* to give a syrup containing crude acid. To a well stirred solution of acid in MeOH at 0°C is added TMS diazomethane until the reaction mixture keeps a light yellow color. The addition of 1 drop of acetic acid, glacial and thin layer chromatography verifies the reaction has gone to completion. The reaction solution is concentrated *in vacuo*

and is purified *via* flash chromatography on silica gel eluting with 30% EtOAc in hexanes yielding **16f**.

e. **Methyl 7-(2-hydroxy-4-(*o*-bromobenzyloxy)-5-formyl-cyclopentyl) hept-5-enoate (16g):** In a round-bottomed flask with a magnetic stir bar is placed an amount of the ketal, **16f**. To this flask is added a sufficient amount of a mixture of 2 parts acetone to 1 part 1N HCl to bring the ketal completely into solution. This material is stirred until, by TLC, the starting material is consumed, typically overnight. The crude mixture, containing the product **16g**, is extracted with ether, and the ether extract re-esterified *in situ* with, preferably, TMS-diazomethane. The organic extracts were concentrated under reduced pressure at 0°C and used immediately without further purification.

f. **Dimethyl-3-(2-fluorophenoxy)-2-oxo-butylphosphonate (16j):** In a flame-dried, round-bottomed flask equipped with a stir bar and thermometer is placed dimethylmethyl phosphonate (1.0 equiv.) in anhydrous THF. The solution is cooled to -78°C and treated with *n*-butyllithium (1.05 equiv.). The reaction mixture is allowed to stir for 15 minutes. To this solution is added methyl-2-(2-fluorophenoxy)propionate (1.1 equiv.) in anhydrous THF. The mixture is allowed to warm to room temperature over the next 6 hours. The mixture is treated with a saturated solution of ammonium chloride and extracted with CH₂Cl₂. The organic layer is washed with water followed by brine. The combined aqueous layers are back extracted with CH₂Cl₂ and the organic layers combined, dried over anhydrous MgSO₄, filtered, and concentrated under reduced pressure. Purification is effected by silica gel column chromatography (hexane/ethyl acetate/ 2-propanol 45/50/5 to hexane/ethyl acetate/2-propanol 40/50/10) to yield 1.34 g (70%) of dimethyl-4-(2-fluorophenyl)-2-oxo-butylphosphonate (**16j**) as an oil.

g. **11-*o*-Bromobenzyloxy-16-(2-fluorophenoxy)-17-trinor-15-oxo-PGF_{2a} methyl ester (16k):** In a flame-dried, round-bottomed flask equipped with a magnetic stirbar is placed dimethyl-4-(2-fluorophenyl)-2-oxo-butylphosphonate (**16j**) (1.43 equiv) in DME and water. To this solution is added lithium bromide (1.65 equiv), triethylamine (1.65 equiv), and (**16g**) (1.0 equiv). The solution is stirred at room temperature for 48 hours. At this point additional triethylamine and water is added and the solution is stirred for an additional hour. The solution is poured into brine and extracted with 3 portions of ethyl acetate. The organic layers are combined, dried over anhydrous MgSO₄, filtered, and concentrated under reduced pressure.

Purification is effected by silica gel column chromatography (dichloromethane/methanol 19/1) to give 11-*o*-bromobenzyloxy-17-(2-fluorophenyl)-17-trinor-15-oxo-PGF_{2a} methyl ester (**1k**) as an oil.

h. 11-*o*-Bromobenzyloxy-15-(*R,S*)-16-(2-fluorophenoxy)-17-trinor-PGF_{2a} methyl ester (16l): In a flame-dried round-bottomed flask equipped with a stir bar is placed 17-(2-fluorophenyl)-17-trinor-15-oxo-PGF_{2a} methyl ester (**16k**) (1.0 equiv), cerium trichloride (1.05 equiv) in methanol. The solution is stirred at room temperature for 5 minutes. The solution is cooled to -10°C and sodium borohydride (1.02 equiv.) in methanol is added. The solution is stirred at -10°C for 3 hours. The mixture is treated with water and the pH brought to 6-7 with 1N hydrochloric acid. The mixture is extracted twice with ethyl acetate, and the organic layers combined, dried over anhydrous MgSO₄, filtered and concentrated under reduced pressure. Purification is effected by silica gel column chromatography (3% methanol in dichloromethane to 5% methanol in dichloromethane) to give the 15 (*R*) epimer and the 15 (*S*) epimer as colorless oils.

i. 9,15-bis-*tert*-butyldimethylsilyloxy-13,14-dihydro-16-(2-fluorophenoxy)-17-trinor-PGD₂ methyl ester (16m): In a round-bottomed flask equipped with a magnetic stirbar, is stirred a solution of **16l** (1 equiv) in CH₂Cl₂. To this solution is added dropwise at -78°C 2,6-lutidine (2.9 equiv.) followed by TBDMSOTf (2.8 equiv.). The reaction stirred for 30 minutes at -78°C and then warmed to 25°C overnight. The reaction is quenched with water. The organic layer is washed with water, dried over MgSO₄, and concentrated *in vacuo* to give a yellow oil which is subjected to flash chromatography on silica gel eluting with hexanes then 1% MeOH in CH₂Cl₂. The product is then washed with 1N HCl, 0.1N HCl, water, and brine to give the *bis*-protected intermediate. This intermediate is placed in a flame-dried round-bottomed flask equipped with a stir bar. Tri-*n*-butyl tin hydride is added to Ether and the reaction is stirred for 24 hours. Quenching with 1N HCL and then back washing the organics 2 with with brine. Dry over MgSO₄ and the organic layer is concentrated under reduced pressure and chromatographed to yield the PGD analog **16m**.

j. 11-oximyl-13,14-dihydro-16-(2-fluorophenoxy)-17-trinor-PGD₂ (16n): A round-bottomed flask equipped with a stirbar is cooled to 0° C and the methyl ester (**16m**) and a solution of HF in pyridine are added. The solution is allowed to warm to room temperature and followed by TLC. Upon consumption of the starting


material, the solution is concentrated and partitioned between ethyl acetate and 0.1% aqueous sodium carbonate. The organic extracts are combined and chromatographed and the crude product is stirred overnight with hydroxylamine and sodium acetate (1:9) in 1:1:3 *p*-dioxane: water: methanol. The mixture is concentrated under reduced pressure and added is lithium hydroxide monohydrate (1.8 equiv) in a 50/50 THF/water solution. The mixture is stirred at room temperature for 6 hours and then diluted with water and acidified to pH 2-3 with 1N HCl. The aqueous phase is extracted 3 times with ethyl acetate and the organic layers combined. The combined organic layers were dried over anhydrous MgSO_4 , filtered, and concentrated under reduced pressure to yield the crude acid. Purification is effected by HPLC to yield an analytical sample of **16n**.

Examples 17-28

Examples 17-28 are prepared using substantially the same procedures as those described in **Example 16**, substituting the appropriate starting materials. The skilled artisan may change temperature, pressure, atmosphere, solvents or the order of reactions as appropriate. Additionally, the skilled artisan may use protecting groups to block side reactions or increase yields as appropriate. All such modifications can readily be carried out by the skilled artisan in the art of organic chemistry, and thus are within the scope of the invention.

Example 17





11-oximyl-16-(2,4-difluorophenylthio)-17-trinor-PGD₂ methyl ester






Example 18





11-oximyl-16-aza-(3,5-difluorophenyl)-17-trinor PGD₂

32


**Example 19****11-oximyl-16-(2-fluorophenylthio)-17-trinor-PGD₂ methyl ester****Example 20****11-oximyl-16-(4-fluorophenoxy)-16-tetranor PGD₂ ethyl ester****Example 21****11-oximyl-16-(4-fluorophenylthio)-16-tetranor PGD₂**

Example 22**11-oximyl-16-(2-methoxyphenoxy)- 16-tetranor PGD₂****Example 23****11-oximyl-16-(3-methoxyphenoxy)- 16-tetranor PGD₂ isopropyl ester****Example 24****11-oximyl-17-oxo-(2-methyl-thienyl)-18-dinor PGD₂ methyl ester****Example 25****11-oximyl-16-((3-trifluoromethyl)phenoxy)- 16-tetranor PGD₂ methyl ester**

34

**Example 26****11-oximyl-16-(2-methylphenoxy)-16-tetranor PGD₂ methyl ester****Example 27****11-oximyl-16-(3-methylphenoxy)-16-tetranor PGD₂****Example 28****11-oximyl-16-phenoxy-16-tetranor PGD₂****Example 29**

Preparation of 11-oximyl-13,14-dihydro-16-phenylthio 16-tetranor PGD 1α (29b):



Compound 1i from **Example 1** is treated with sodium cyanoborohydride in THF: acetic acid (1:1) and allowed to react for 2 hours. The mixture is quenched with 1 N HCl and washed with brine twice. The organic layer is dried over magnesium sulfate and reduced under pressure. The resulting oil is chromatographed using 30% ethyl acetate: hexane. Appropriate fractions were combined and reduced to a yellow oil, yielding **29a**. Deprotection is accomplished by methods described above, yielding **29b**.


Examples 30-34

Examples 30-34 are prepared using substantially the same procedures as those described in **Example 29**, substituting the appropriate starting materials. The skilled artisan may change temperature, pressure, atmosphere, solvents or the order of reactions as appropriate. Additionally, the skilled artisan may use protecting groups to block side reactions or increase yields as appropriate. All such modifications can readily be carried out by the skilled artisan in the art of organic chemistry, and thus are within the scope of the invention.


Example 30

11-hydroxylamino-13,14-dihydro-16-(3-chlorophenoxy)- 16-tetranor -PGD 1


36

**Example 31**


11-hydroxylamino -13,14-dihydro-16-(2,4-difluorophenylthio)- 16-tetranor
PGD₁ methyl ester

**Example 32**

11-hydroxylamino-13,14-dihydro-16-aminophenyl-16-tetranor -PGD₁
methyl ester



**Example 33**

11-hydroxylamino-13,14-dihydro-16-(4-fluorophenylthio)- 16-tetranor PGD₁
ethyl ester

**Example 34**

11-hydroxylamino- 13,14- dihydro-16- (4-fluorophenoxy)- 16-tetranor PGD₁

37

**Example 35****11-hydroxylamino-16-phenoxy-16-tetranor-1-tetrazolyl PGD₂**





11-oximyl-16-phenoxy-16-tetranor-1-tetrazolyl PGD₂ is prepared using substantially the same procedures as those described in Example 16, substituting the tetrazolyl phosphonium salt for the carboxylate and phenyl for the o-fluorophenyl. To this compound (35a) is added 1.5 equiv. of sodium cyanoborohydride in a 1:1 mixture of acetic acid and tetrahydrofuran. The reaction is monitored by TLC. After complete consumption of starting material, the reaction is diluted with water and exhaustively extracted with EtOAc, yielding the hydroxylamine.

Examples 36-40



Examples 36-40 are prepared using substantially the same procedures as those described in **Example 35**, substituting the appropriate starting materials. The skilled artisan may change temperature, pressure, atmosphere, solvents or the order of reactions as appropriate. Additionally, the skilled artisan may use protecting groups to block side reactions or increase yields as appropriate. All such modifications can readily be carried out by the skilled artisan in the art of organic chemistry, and thus are within the scope of the invention.

Example 36**11-hydroxylamino-16-phenylthio-16-tetranor -PGD_{2a}**

38

**Example 37****11-hydroxylamino -20-ethoxy- PGD₂a****Example 38****11-methoxylamino -16-(3,5-difluorophenoxy)- 16-tetranor PGD₂a****Example 39****11-hydroxylamino-16-(3-thiofuranyl)-17-trinor-PGD₂a****Example 40****11-hydroxylamino-16-((3-trifluoromethyl)phenoxy)-17-trinor PGD₂a**

methyl ester

**Example 41****11-oximyl-15-methyl-16-2-fluorophenoxy-17-trinor-PGD₂ methyl ester**

Compound **16k** from **Example 16** is dissolved in dry THF and 1.2 equiv. of TBDMSOTf and 1.5 equiv. of 2,6 lutidine are added. Standard work-up yields the TBDMS-protected version of **16k**, which is dissolved in THF. Addition of the methylcerium nucleophile (~1.5 equiv.) (for examples of cerium chloride-mediated nucleophilic addition see: T. Imamoto, et al., "Carbon-Carbon Bond Forming Reactions Using Cerium Metal or Organocerium (III) Reagents", *J. Org. Chem.* Vol. 49 (1984) p. 3904-12; T. Imamoto, et al., "Reactions of Carbonyl Compounds with Grignard Reagents in the Presence of Cerium Chloride", *J. Am. Chem. Soc.* Vol. 111 (1989) p. 4392-98; and references cited therein) gives the product **S41c**, which after purification is dissolved in liquid ammonia and a sufficient amount of lithium metal is added to effect deprotection of the benzyl ether. After purification,


the deprotected **S41c** is condensed with hydroxylamine as described in **Example 1** and deprotected to yield the title compound, **S41d**.

Examples 42-43

Examples 42-43 are prepared using substantially the same procedures as those described in **Example 41**, substituting the appropriate starting materials. The skilled artisan may change temperature, pressure, atmosphere, solvents or the order of reactions as appropriate. Additionally, the skilled artisan may use protecting groups to block side reactions or increase yields as appropriate. All such modifications can readily be carried out by the skilled artisan in the art of organic chemistry, and thus are within the scope of the invention.


Example 42

11-oximyl-15-ethyl-17-phenoxy-18-dinor-PGD₂




Example 43

3-oxo-11-oximyl-13,14-dihydro-15-methyl-16-phenoxy-16-tetranor -PGD_{1α}



Example 44


3-oxo-11-hydroxylamino-13,14-dihydro-15-methyl-16-phenoxy-16-tetranor-PGD_{1α}



To a 50 mL round bottom flask is **3-oxo-11-oximyl-13,14-dihydro-15-methyl-16-phenoxy-17-trinor-PGD₂** (from **Example 43**) and 1.5 equiv. of sodium cyanoborohydride in a 1:1 mixture of acetic acid and tetrahydrofuran. The reaction is monitored by TLC. After complete consumption of starting material, the reaction is diluted with water, the pH is adjusted to 3.0, and exhaustively extracted with EtOAc, yielding the title hydroxylamine-containing PGF analog.

Example 45

11-oximyl-15-methyl-15-deoxy-15-methamino-16-2-fluorophenoxy-16-tetranor-PGD₂ methyl ester




Compound **16k** from **Example 16** is dissolved in dry THF and 1.2 equiv. of TBDMSTf and 1.5 equiv. of 2,6 lutidine are added. Standard work-up yields the TBDMS-protected version of **16k**, which is dissolved in THF and condensed with methylamine to give the intermediate imine. Addition of the methylcerium

nucleophile (~1.5 equiv.) (for examples of cerium chloride-mediated nucleophilic addition see: T. Imamoto, et al., "Carbon-Carbon Bond Forming Reactions Using Cerium Metal or Organocerium (III) Reagents", *J. Org. Chem.* Vol. 49 (1984) p. 3904-12; T. Imamoto, et al., "Reactions of Carbonyl Compounds with Grignard Reagents in the Presence of Cerium Chloride", *J. Am. Chem. Soc.* Vol. 111 (1989) p. 4392-98; and references cited therein) gives the product **S45b**, which after purification is dissolved in THF and a sufficient amount of tri-*n*-butyl tin hydride is added to effect the oxidative removal of the benzyl ether. After purification, **S45c** is condensed with hydroxylamine as described in **Example 16** and deprotected to yield the title compound, **S45d**.

Example 46


11-hydroxylamino-15-methyl-15-deoxy-15-methylamino-16-2-fluorophenoxy-16-tetranor -PGF₂, methyl ester



To a 50 mL round bottom flask is charged **11-oximyl-15-methyl-15-deoxy-15-methamino-16-*o*-fluorophenoxy-17-trinor-PGD₂ methyl ester (Example 45)** and 1.5 equiv. of sodium cyanoborohydride in a 1:1 mixture of acetic acid and tetrahydrofuran. The reaction is monitored by TLC. After complete consumption of starting material, the reaction is diluted with water and exhaustively extracted with EtOAc, yielding the title hydroxylamine-containing PGF analog.

Example 47

Preparation of 11-oximyl-13,14-dihydro-16-((3-trifluoromethyl)phenoxy)-16-tetranor- PGD₁ 1-hydroxamic acid:




In a flame-dried 25 mL round-bottomed flask equipped with a magnetic stirbar is placed **11-oximyl-13,14-dihydro-16-((3-trifluoromethyl) phenoxy)- 17-trinor- PGD₁ methyl ester (Example 12)** (1.0 equiv.) in methanol. To this solution is added hydroxylamine in methanol (1.25 equiv.). The solution is stirred for 18 hours. The solution is then treated with 1N hydrochloric acid and thrice extracted with ethyl acetate. The organic layer is washed with saturated aqueous sodium chloride, dried over anhydrous MgSO₄, filtered and concentrated under reduced pressure. The residue is purified by chromatography to give **11-oximyl-13,14-dihydro-16-((3-trifluoromethyl) phenoxy)- 16-tetranor - PGD₁ 1-hydroxamic acid**.

Example 48

Example 48 is prepared using substantially the same procedures as those described in **Example 47**, substituting the appropriate starting materials. The skilled artisan may change temperature, pressure, atmosphere, solvents or the order of reactions as appropriate. Additionally, the skilled artisan may use protecting groups to block side reactions or increase yields as appropriate. All such modifications can readily be carried out by the skilled artisan in the art of organic chemistry, and thus are within the scope of the invention.

Example 48

11-oximyl-16-phenoxy-17-trinor-PGD₂ 1-N-methanesulfonamide



Compositions

Compositions of the subject invention comprise a safe and effective amount of the subject compounds, and a pharmaceutically-acceptable carrier. As used herein, "safe and effective amount" means an amount of a compound sufficient to significantly induce a positive modification in the condition to be treated, but low enough to avoid serious side effects (at a reasonable benefit/risk ratio), within the scope of sound medical judgment. A safe and effective amount of a compound will vary with the particular condition being treated, the age and physical condition of the patient being treated, the severity of the condition, the duration of the treatment, the nature of concurrent therapy, the particular pharmaceutically-acceptable carrier utilized, and like factors within the knowledge and expertise of the attending physician.

In addition to the compound, the compositions of the subject invention contain a pharmaceutically-acceptable carrier. The term "pharmaceutically-acceptable carrier", as used herein, means one or more compatible solid or liquid filler diluents or encapsulating substances which are suitable for administration to a subject. The term "compatible", as used herein, means that the components of the composition are capable of being commingled with the compound, and with each other, in a manner such that there is no interaction which would substantially reduce the pharmaceutical efficacy of the composition under ordinary use situations. Pharmaceutically-acceptable carriers must, of course, be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the subject being treated.

Some examples of substances which can serve as pharmaceutically-acceptable carriers or components thereof are sugars, such as lactose, glucose and sucrose; starches, such as cornstarch and potato starch; cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, cellulose acetate; powdered tragacanth; malt; gelatin; talc; solid lubricants, such as stearic acid, magnesium stearate; calcium sulfate; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and oil of theobroma; polyols such as propylene glycol, glycerin, sorbitol, mannitol, and polyethylene glycol; alginic acid; emulsifiers, such as the Tweens®; wetting agents such as sodium lauryl sulfate; coloring agents; flavoring agents, excipients; tableting agents; stabilizers; antioxidants; preservatives; pyrogen-free water; isotonic saline; and phosphate buffer solutions.

The choice of a pharmaceutically-acceptable carrier to be used in conjunction with a compound is basically determined by the way the compound is to be administered. The compounds of the present invention may be administered

systemically. Routes of administration include transdermal; oral; parenterally, including subcutaneous or intravenous injection; topical; and/or intranasal.

The appropriate amount of the compound to be used may be determined by routine experimentation with animal models. Such models include, but are not limited to the intact and ovariectomized rat models, the ferret, canine, and non human primate models as well as disuse models.

Preferred unit dosage forms for injection include sterile solutions of water, physiological saline, or mixtures thereof. The pH of said solutions should be adjusted to about 7.4. Suitable carriers for injection or surgical implants include hydrogels, controlled- or sustained release devices, polylactic acid, and collagen matrices.

Suitable pharmaceutically-acceptable carriers for topical application include those suited for use in lotions, creams, gels and the like. If the compound is to be administered perorally, the preferred unit dosage form is tablets, capsules and the like. The pharmaceutically-acceptable carriers suitable for the preparation of unit dosage forms for oral administration are well-known in the art. Their selection will depend on secondary considerations like taste, cost, and shelf stability, which are not critical for the purposes of the subject invention, and can be made without difficulty by those skilled in the art.

Methods of Use

The compounds of the present invention are useful in treating many medical disorders, including for example, ocular disorders, hypertension, fertility control, nasal congestion, neurogenic bladder disorder, gastrointestinal disorders, dermatological disorders, and osteoporosis.

The compounds of the present invention are useful in increasing (1) bone volume and trabecular number through formation of new trabeculae, (2) bone mass while maintaining a normalized bone turnover rate, and/or (3) formation at the endosteal surface without removing bone from the existing cortex. Thus, these compounds are useful in the treatment and prevention of bone disorders.

The preferred routes of administration for treating bone disorders are transdermal and intranasal. Other preferred routes of administration include rectal, sublingual, and oral.

The dosage range of the compound for systemic administration is from about 0.01 to about 1000 $\mu\text{g/kg}$ body weight, preferably from about 0.1 to about 100 $\mu\text{g/kg}$ per body weight, most preferably from about 1 to about 50 $\mu\text{g/kg}$ body weight per day. The transdermal dosages will be designed to attain similar serum or plasma

levels, based upon techniques known to those skilled in the art of pharmacokinetics and transdermal formulations. Plasma levels for systemic administration are expected to be in the range of 0.01 to 100 nanograms/ml, more preferably from 0.05 to 50 ng/ml, and most preferably from 0.1 to 10 ng/ml. While these dosages are based upon a daily administration rate, weekly or monthly accumulated dosages may also be used to calculate the clinical requirements.

Dosages may be varied based on the patient being treated, the condition being treated, the severity of the condition being treated, the route of administration, etc. to achieve the desired effect.

The compounds of the present invention are also useful in decreasing intraocular pressure. Thus, these compounds are useful in the treatment of glaucoma. The preferred route of administration for treating glaucoma is topically.

Composition and Method Examples

The following non-limiting examples illustrate the subject invention. The following composition and method examples do not limit the invention, but provide guidance to the skilled artisan to prepare and use the compounds, compositions and methods of the invention. In each case other compounds within the invention may be substituted for the example compound shown below with similar results. The skilled practitioner will appreciate that the examples provide guidance and may be varied based on the condition being treated and the patient.

Example A

Pharmaceutical compositions in the form of tablets are prepared by conventional methods, such as mixing and direct compaction, formulated as follows:

<u>Ingredient</u>	<u>Quantity (mg per tablet)</u>
Compound of Example 1	5
Microcrystalline Cellulose	100
Sodium Starch Glycollate	30
Magnesium Stearate	3

When administered orally once daily, the above composition substantially increases bone volume in a patient suffering from osteoporosis.

Example B

Pharmaceutical compositions in liquid form are prepared by conventional methods, formulated as follows:

<u>Ingredient</u>	<u>Quantity</u>
Compound of Example 32	1 mg
Phosphate buffered physiological saline	10 ml
Methyl Paraben	0.05ml

When 1.0 ml of the above composition is administered subcutaneously once daily, the above composition substantially increases bone volume in a patient suffering from osteoporosis.

Example C


Topical pharmaceutical compositions for lowering intraocular pressure are prepared by conventional methods and formulated as follows:

<u>Ingredient</u>	<u>Amount (wt %)</u>
Compound of Example 1	0.004
Dextran 70	0.1
Hydroxypropyl methylcellulose	0.3
Sodium Chloride	0.77
Potassium chloride	0.12
Disodium EDTA (Edetate disodium)	0.05
Benzalkonium chloride	0.01
HCL and/or NaOH	pH 7.2-7.5
Purified water	q.s. to 100%

While particular embodiments of the subject invention have been described, it would be obvious to those skilled in the art that various changes and modifications to the compositions disclosed herein can be made without departing from the spirit and scope of the invention. It is intended to cover, in the appended claims, all such modifications that are within the scope of this invention.

WHAT IS CLAIMED IS:

1. A compound having the structure:



characterized in that

- (a) R₁ is CO₂H, C(O)NHOH, CO₂R₇, CH₂OH, S(O)₂R₇, C(O)NHR₇, C(O)NHS(O)₂R₇, or tetrazole; characterized in that R₇ is alkyl, heteroalkyl, monocyclic carbocyclic aliphatic ring, monocyclic heterocyclic aliphatic ring, monocyclic aromatic ring, or monocyclic heteroaromatic ring;
- (b) W is O, NH, S, S(O), S(O)₂, or (CH₂)_m; characterized in that m is an integer from 0 to about 3;
- (c) R₂ is H and R₃ is H or lower alkyl, or R₂ and R₃ together form a covalent bond;
- (d) R₄ is H, alkyl, heteroalkyl, monocyclic carbocyclic aliphatic ring, monocyclic heterocyclic aliphatic ring, monocyclic aromatic ring, or monocyclic heteroaromatic ring;
- (e) each R₅ is independently selected from the group consisting of H, CH₃, and C₂H₅;
- (f) X is NHR₈ or OR₈, characterized in that each R₈ is independently selected from the group consisting of H, acyl, alkyl, heteroalkyl, monocyclic carbocyclic aliphatic ring, monocyclic heterocyclic aliphatic ring, monocyclic aromatic ring, and monocyclic heteroaromatic ring;

- (g) each R_6 is independently selected from the group consisting of H, CH_3 , C_2H_5 , OR_8 , and NHR_8 ;
- (h) Y is O, NHR_8 , S, $S(O)$, or $S(O)_2$, provided no carbon has more than one heteroatom attached to it;
- (i) Z is H, methyl, monocyclic carbocyclic aliphatic ring, monocyclic heterocyclic aliphatic ring, monocyclic aromatic ring, monocyclic heteroaromatic ring, bicyclic carbocyclic aliphatic ring, bicyclic heterocyclic aliphatic ring, bicyclic aromatic ring, or bicyclic heteroaromatic ring, provided that when Y is S, $S(O)$, or $S(O)_2$ and Z is H, q is at least 1;
- (j) a and b are independently selected from the group consisting of single bond, cis double bond, and trans double bond;
- (k) p is an integer from 1 to 5, q is an integer from 0 to 5, and p + q is 1 to 5; and

any optical isomer, diastereomer, enantiomer of the above structure or a pharmaceutically-acceptable salt, or bio-hydrolyzable amide, ester, or imide thereof.

2. The compound of Claim 1 characterized in that R_1 is CO_2H , $C(O)NHOH$, CO_2R_7 , $C(O)NHS(O)_2R_7$, or tetrazole.
3. The compound of Claim 1 or 2 characterized in that R_4 and R_5 are each H and X is OH.
4. The compound according to any of the preceding claims characterized in that p + q is 1 or 2 and Z is monocyclic aromatic ring or monocyclic heteroaromatic ring.
5. The compound of Claim 1, 2 or 3 characterized in that p + q is 3 to 5 and Z is H or methyl.

6. The compound according to any of the preceding claims characterized in that W is $(\text{CH}_2)_1$.
7. The compound according to any of the preceding claims characterized in that a is a cis double bond and b is a trans double bond.
8. The use of a compound according to any of the preceding claims in the manufacture of a medicament for treating a bone disorder in a human or other mammal.
9. The use of Claim 8 characterized in that said bone disorder is osteoporosis.
10. The use of a compound according to any of the preceding claims in the manufacture of a medicament for treating glaucoma in a human or other mammal.

INTERNATIONAL SEARCH REPORT

Internat I Application No

PCT/IB 99/00480

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07C405/00 //A61K31/557

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	GB 1 236 227 A (CIBA-GEIGY) 23 June 1971 see claims ---	1-10
A	FR 2 182 928 A (CIBA GEIGY AG) 14 December 1973 see claims ---	1-10
A	ELLIS C K ET AL: "Metabolism of prostaglandin D2 in the monkey." JOURNAL OF BIOLOGICAL CHEMISTRY, (1979 MAY 25) 254 (10) 4152-63. JOURNAL CODE: HIV. ISSN: 0021-9258., XP002105896 United States see page 4154, column 1 - column 2; figure 20 -----	1-10

☐ Further documents are listed in the continuation of box C

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"C" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

15 June 1999

Date of mailing of the international search report

25/06/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Berte, M

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 99/00480

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 1236227 A	23-06-1971	BE 715492 A	21-11-1968
		CA 926412 A	15-05-1973
		CH 505774 A	15-04-1971
		DE 1768434 A	01-07-1971
		FR 1563495 A	11-04-1969
		GB 1236226 A	23-06-1971
		NL 6807186 A	25-11-1968
		SE 363625 B	28-01-1974
		US 3532721 A	06-10-1970
		US 3538120 A	03-11-1970
FR 2182928 A	14-12-1973	BE 797732 A	04-10-1973
		DE 2315355 A	18-10-1973
		JP 49013107 A	05-02-1974
		NL 7304753 A	09-10-1973
		US 3843713 A	22-10-1974
		US 3890369 A	17-06-1975
		US 3798275 A	19-03-1974

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

This Page Blank (uspto)